Andrew Cittadine - 02 Dec 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Operating Officer
Signature
/s/ Quan Vu, Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
02 Dec 2025
Transactions value $
$0
Form type
4
Filing time
08 Dec 2025, 16:50:48 UTC
Previous filing
02 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cittadine Andrew Chief Operating Officer 1000 SKOKIE BLVD SUITE 350, WILMETTE /s/ Quan Vu, Attorney-in-fact 08 Dec 2025 0001863624

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +8.97K $0.00 8.97K 02 Dec 2025 Common Stock 8.97K $75.94 Direct F1
transaction MNPR Restricted Stock Units Award $0 +13.9K +35.99% $0.00 52.6K 02 Dec 2025 Common Stock 13.9K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options vest 6/48ths on June 30, 2026, and 1/48th per month thereafter.
F2 RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter.